Introduction
Transcription factor PU.1, a member of the ETS family, is exclusively expressed in hematopoietic cells, where it plays an essential regulatory role in normal myelomonocytic and lymphoid differentiation. 1 In fact, PU.1-deficient hematopoietic stem cells (HSC) fail to develop into the earliest myeloid and lymphoid progenitors and PU.1-deficient mice have a block in the development of both cell lineages.
2-4 PU.1 regulates almost every myeloid gene promoter studied to date, for example, granulocyte-macrophage-colony stimulating factor receptor alpha (GM-CSFRa), M-CSFR, CD13. [5] [6] [7] In addition to this activating role on myeloid gene expression, PU.1 was also shown to suppress gene activation by interfering with the DNA binding of other transcription factors. This capacity of PU.1 has been particularly well studied in erythropoietic precursors, where PU.1 interacts with GATA-1, the master regulator of erythropoiesis, blocks its DNA binding, and thus inhibits erythroid differentiation. [8] [9] [10] [11] Besides its crucial function in normal hematopoiesis, a role of PU.1 in tumorigenesis is suggested by murine models of acute myeloid leukemia (AML). Mice exhibiting a reduced/absent PU.1 expression were shown to spontaneously develop AML, 12, 13 and in another model PU.1 mutations were found to facilitate radiation-induced AML. 14, 15 Interestingly, several recent reports linked altered PU.1 function also to the development of AML in humans:
(a) in a small number of AML cases (9/126), heterozygous mutations of PU.1 associated with decreased PU.1 function were observed; in particular in 3/39 patients with AML M4 without inv (16) . 16 This observation was not confirmed by other groups; [17] [18] [19] (b) changes in the activity of other transcription factors owing to translocations (e.g. t (15, 17) , t (8, 21) , Flt3 mutations) were associated with decreased PU.1 expression in AML M3 and in some cases of AML M2; [20] [21] [22] [23] (c) PU.1 protein hyperphosphorylation was observed in some subtypes of AML. 24 Iron et al. 25 exposed human CD34 þ to hydroxyquinone, a benzene metabolite, and found a marked PU.1 hyperphosphorylation, associated with an enhanced clonogenic activity and a block in myeloid differentiation. These studies could eventually explain the link between chronic exposure to high concentrations of benzene and AML development; (d) recently, two transcription factors of the Jun family were identified as PU.1 target genes. Lentiviral overexpression of JunB in PU.1 knockdown preleukemic HCSs led to the loss of leukemic self-renewing capacity in these cells, and overexpression of c-Jun to restored monocytic differentiation. In some AML patients, low PU.1 levels in HSCs correlated with low levels of JunB, thus suggesting a role of JunB in the malignant self-renewal of leukemic stem cells in AML. 26 In the present work, we wanted to study whether overexpression of PU.1 might influence phenotype and restore differentiation of primary myeloid leukemic blasts, independent of pretransduction PU.1 levels. For this purpose we designed a lentivector overexpressing PU.1. Upon transduction of cells from myeloid cell lines and blasts from patients with AML, various PU.1 target genes were specifically induced or silenced. Phenotype, differentiation, cell-cycle kinetics and apoptosis rates were influenced. Indeed, increases in PU.1 protein levels induced blasts to change their phenotype to a differentiated, nonproliferating cell prone to apoptosis. We propose therefore that increase of PU.1 expression in leukemic blasts allows to overcome the differentiation block present in these cells. Direct modulation of PU.1 could therefore constitute a new therapeutic approach in AML. Puc8 containing complete PU.1 cDNA and pBLCAT2Fes3X (wild type and mutated), containing PU.1 responsive elements, were kind gift from F Moreau-Gachelin (INSERM, Institut Curie, Paris, France). pBLCAT2Fes3X plasmids were described previously 27 and were renamed PU.1-REwt and PU.1-REmut for our study. The packaging plasmid pCMVR8.91 and the envelope plasmid pMD.G for lentivirus production and pWPIR-GFP, were obtained from D. Trono (EPFL, Lausanne, Switzerland). Maps and sequences are available at http://tronolab.epfl.ch/.
Materials and methods

Materials
For Western blot analysis, the rabbit polyclonal immunoglobulin (IgG) anti-PU.1 Ab (sc352), and the goat polyclonal IgG anti-actin Ab (sc1615) were used (Santa Cruz Biotechnology, Santa Cruz, CA, USA). For flow cytometric analysis, we used anti-CD235a, anti-CD38 and anti-CD13, coupled to PE (Dako Diagnostics, Copenhagen, Denmark); Annexin V, anti-CD14, anti-CD11c and anti-CD36, coupled to PE; anti-CD4 and anti-CD45, coupled to APC (BD Biosciences, San Jose, CA), anti-CD16, coupled to PC-5 (Beckman Coulter, Fullerton, CA, USA) and anti-CD52, coupled to PE (Serotec, Oxford, UK).
Construction of lentivectors
Puc8 containing PU.1. cDNA was digested by EcoR1, and the resulting fragment (1168 bps) subcloned into EcoR1-digested pBluescript KS (Stratagene, La Jolla, CA, USA). The resulting plasmid was then digested by BamH1/Sal1 and the fragment containing PU.1 cDNA (1242 bps) cloned into BamH1/Sal1-digested pWPIR-GFP lentivector. The resulting vector was named LV-PU.1 and the empty vector pWPIR-GFP was renamed LV-empty.
High titer production of lentivectors was achieved by transiently cotransfecting 293 T cells with pCMVR8.91, pMD.G and the lentivector of interest, as described previously. 28 
RNA Isolation and RT-PCR analysis
Total cellular RNA was extracted with TRIZOL (Invitrogen) according to manufacturer's instructions. First-strand cDNA was synthesized using MMLV reverse transcriptase (Invitrogen), and cDNAs were amplified by polymerase chain reaction (PCR) using the following primers ( In addition to conventional PCR, real-time PCR was performed using the LightCycler instrument (Roche) and QuantiTect SYBR Green PCR Master Mix (Qiagen, Hilden, Germany), according to the manufacturer's instructions. LV-PU.1 was used to establish the PU.1 standard curve, total reverse transcribed RNA from Hela cells was used for the GAPDH standard curve. Results were normalized to GAPDH and expressed as arbitrary units.
Western blot analysis
To obtain total cellular extracts, cells were lysed in a lysis buffer (Tris (tris(hydroxymethyl) aminomethane) 50 mM (pH 8), 250 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate and protease inhibitor cocktail (Sigma). Samples were cleared by centrifugation at 12000 g at 41C. Fifty micrograms of proteins were boiled for 5 min in the presence of 2-mercaptoethanol, resolved on a 12% polyacrylamide gel and transferred to a 0.45 mm pore size nitrocellulose membrane (Biorad, Hercules, CA, USA). Membranes were blocked using 5% (10% for PU.1) non-fat dried milk in phosphate-buffered saline containing 0.1% Tween 20 and exposed to antibodies overnight at 41C in the same buffer (anti-PU.1, and anti-actin diluted 1/500). After incubation with appropriate secondary antibodies conjugated to horseradish peroxidase, immunoreactivity was detected using an enhanced chemiluminescence detection kit (GE Healthcare, Little Chalfont, UK). The same membranes were exposed to the two different antibodies.
Gene reporter analysis
A total of 3 Â 10 5 293 T cells/well were plated on a six-well plate and cotransfected 1 day later using calcium phosphate precipitation method. 28 . Briefly, 500 ng of reporter genes (PU.1-REwt or PU.1-REmut) were mixed with LV-PU.1 or LV-empty. Precipitates were applied on cells, which were lysed 48 h later. Chloramphenicol acetyl transferase (CAT) activity was measured using a CAT enzyme-linked immunosorbent assay (ELISA) kit (Roche), according to manufacturer's instructions. Plates were read on an ELISA plate reader (Molecular Devices, Sunnyvale, CA, USA).
Flow cytometric analysis and cell sorting
Cells were stained with appropriate antibodies and fixed with 'cell fix' reagent (BD Biosciences), before analysis on a FACScalibur (BD Biosciences). For cell cycle analysis, the APC BrdU Flow kit (BD Pharmingen) was used, according to manufacturer's instructions. For cell sorting, a FACstar was used (operated by D Wohlwend, University Medical Center, Geneva).
Culture of primary AML blasts
Bone marrow samples from 12 patients with AML were obtained according to institutional guidelines. Each bone marrow sample contained more than 90% blasts. Diagnosis was established using Lentiviral PU.1 overexpression S Durual et al standard morphologic, cytogenetic and immunophenotypic criteria (WHO classification; Table 1 ). After Ficoll-paque gradient centrifugation, blast cells were cultured in IMDM medium, supplemented with 15% human plasma AB, 1% sodium pyruvate, 1% penicillin/streptomycin and Epo (2 U/ml), SCF (50 ng/ml), TPO (50 ng/ml), IL-3 (25 ng/ml), G-CSF (100 ng/ml), M-CSF (50 ng/ml) and human holo-transferrin (0.47 mg/ml). 29 
Results
Construction and function tests of a lentivector for PU.1 overexpression
To overexpress PU.1 in human hematopoietic cells, we designed a bicistronic lentivector, LV-PU.1, containing the complete PU.1 cDNA, under the control of the elongation factor 1 (EF1)-a promoter ( Figure 1a ). We transduced Hela cells, which normally do not express PU.1, and found increased PU.1 mRNA (data not shown) and protein production ( Figure 1b ). To test that overexpressed PU.1 could bind its promoter and was functional, we performed a reporter gene experiment, using CAT plasmids in which the TK promoter is governed by three copies of a known nonmutated or mutated PU.1-responsive element (PU.1-RE wt or mut). 27 We transiently transduced 293T cells with LV-PU.1 and PU.1-REwt, and 48 h later observed a dramatic increase in CAT activity compared to controls, that is, cells transfected with LV-PU.1 and PU.1-REmut (Figure 1c) . Subsequently, we asked whether overexpressed PU.1 could activate some of its target genes (CD13, GM-CSF-Ra, and IL-7Ra). Reverse transcriptase PCR (RT-PCR) performed on HL60 cells 8 days after transduction with LV-PU.1, showed expression of the normally undetectable IL-7Ra and GM-CSFRa mRNAs, as well as an increase in CD13 mRNA expression (Figure 1d ).
Lentiviral PU.1. overexpression in AML cell lines
To evaluate the function of PU.1 in AML we used the wellcharacterized myeloid cell line NB4. (Figure 2a) . Then, we analyzed the expression of several myelomonocytic surface markers by flow cytometry. As shown in Figure 2b , NB4 cells transduced with LV-PU.1, and thus expressing GFP, showed higher CD4, CD11c, CD14 and CD16 expression than cells transduced with the LV-empty vector. The marginal increase of CD4 and CD11c expression observed in cells transduced with LV-empty compared to untransduced cells was most probably owing to a 'nonspecific' activation of NB4 cells by the lentiviral transduction process itself. We did not analyze this effect in more detail. The expression of CD13 did not change, as its expression was already maximal in nontransduced cells. Table 2 shows that LV-PU.1 is able to upregulate six out of eight myelomonocytic surface markers tested, with an increase varying between 1.6 and 21-fold.
Microscopic observation of transduced NB4 cells showed the appearance of adherent cells in the culture wells. Giemsa staining confirmed the presence of macrophage-like cells (Figure 2c) .
Similar experiments were performed with HL60, an AML M2 cell line and HEL and K562, two erythroleukemic cell lines (Supplementary Figure 1) . CD14 was upregulated in HL60 cells ATRA and transduction with LV-PU.1 induce similar phenotypic changes in NB4 cells ATRA, a well-known differentiating agent used in the treatment of promyelocytic AML, was shown to exhibit its differentiation stimulatory effect at least in part via its regulation of PU.1 expression. 22 In fact, PU.1 mRNA levels increase after ATRA stimulation. To compare the effects of ATRA to lentiviral PU.1 overexpression, we performed parallel cultures of NB4 cells. We used ATRA at a concentration of 1 mM, described to be sufficient to induce NB4 cell differentiation. 30 PU.1 mRNA levels were quantified 4 and 8 days after ATRA treatment. We observed similar increases in PU.1 mRNA levels (five-to sixfold increase with a maximum at day 4), and similar phenotypic changes, that is, increases in CD11c and CD4 expression, in ATRA-treated and in LV-PU.1-transduced cells (Figure 3a) . Similar effects were also seen on proliferation rates, in apoptosis and cell-cycle kinetics. As assessed by cell counting, we found a twofold decreased proliferation rate in LV-PU.1 transduced or ATRA-treated cells (data not shown). Moreover, ATRA and LV-PU.1 transduction both led to a dramatic increase in apoptosis (Annexin-V and 7AAD staining, Figure 3b ) and a fourfold decrease of cells in the S phase of the cell cycle (Figure 3c) . Together with the increased expression of myelomonocytic surface markers, these changes correspond to induction of a differentiated, nonproliferating, apoptotic phenotype from a highly proliferating, immature myeloid blast. 
Lentiviral PU.1 overexpression influences phenotype and apoptosis of primary AML blasts
We performed experiments on blasts obtained from 12 patients with different types of AML (seven patients with AML M1/M2, 2 with M3 and 3 with M4/M5; Table 1 ). Blasts were cultured with a cocktail of cytokines (SCF, G-CSF, M-CSF, TPO and erythropoietin), transduced at day 1 with LV-PU.1 and cultured for another 7 days. Although our culture medium was supplemented with various myeloid growth factors, we obtained only a very low proliferation rate in most cases (1-38; median ¼ 9), with only one case showing a proliferation rate higher than 10 (data not shown). Transduction efficiency was lower than with myeloid cell lines (Figure 4a ), but PU.1 mRNA increased fourfold (Figure 4b ), similarly as in the NB4 myeloid cell line (Figure 2a) . Then we analyzed expression of the surface markers CD14, CD4 and CD13 on the untransduced (GFPneg) and transduced (GFP þ ) blasts. Dot plots obtained from three typical patients are shown in Figure 4d and a summary of the results for all 12 patients is given in Figure 4c . A clear increase in CD14, CD4 and CD13 expression was observed specifically in LV-PU.1 transduced GFP þ cells, whereas GFPneg, untransduced cells, and cells transduced with LV-empty showed unchanged levels of marker expression. Increase was roughly 1.5 to 2-fold, depending on the marker and the type of AML studied (Figure 4c ). No morphologic changes were observed (data not shown). Similar to the results obtained with the NB4 cell line, transduction of primary AML blasts with LV-PU.1 led to increased apoptosis in the three groups of AML patients, as compared to cells transduced with LV-empty (Figure 5a ). Again increased apoptosis was observed specifically in LV-PU.1 transduced GFP þ blasts. Figure 5b gives a summary of the 12 cases tested, with a mean increase in Annexin-V staining of 2.070.2-fold.
The effect of PU.1 overexpression is dose-dependent Differentiation of myeloid precursors in myeloid or monocytic lineage cells has been reported to be dose-dependent, a higher level of PU.1 transcription factor leading preferentially to a monocytic phenotype. 31 To analyze an eventual dose-dependent effect of lentiviral PU.1 overexpression on myeloid blast differentiation, we first analyzed normal CD34 þ cells cultured in vitro with growth factors in suboptimal conditions. 28 Transduction of these precursors with LV-PU.1 resulted in two cell populations: GFP-high expressing cells with high CD13/45 expression and GFP-low expressing cells with low CD13/45 expression, corresponding to monocytes/macrophages or neutrophils, respectively (Figure 6a) .
To quantify this effect more in detail, we sorted LV-PU.1-transduced NB4 cells expressing high levels of GFP and transduced cells expressing low GFP levels (Figure 6b ). Using RT-PCR and real-time RT-PCR we confirmed that PU.1 mRNA levels were threefold higher in GFP-high compared to GFP-low cells. A detailed analysis of dotplots for CD14 expression in LV-PU.1 transduced cells (Figure 2b) showed that the highest increase in CD14 expression were restricted to GFP-high cells, indicating a threshold effect for PU.1. This effect was observed in NB4 cells and in primary AML blasts (Figure 6c) . Moreover, this dose-dependent effect was also observed by a detailed analysis of CD13, CD4 and CD11c dotplots (Supplementary Figure 2) .
Discussion
In this study we used lentivectors to overexpress the transcription factor PU.1 in myeloid cell lines and in primary AML blasts. We show how this 'artificial' increase of PU.1 levels influences cell surface antigen expression, differentiation, proliferation, cell-cycle kinetics and apoptosis rates of transduced cells.
Previous work on PU.1 in acute leukemia has focused on acute promyelocytic leukemia, harboring the t (15;17) . It has been shown that in the leukemic blasts PU.1 was suppressed and that stimulation with ATRA was able to restore PU.1 expression and to induce neutrophil differentiation. 22 The differentiation block of the myeloid blasts is therefore not definite but reversible. Although all the molecular pathways and effects of ATRA stimulation are not yet completely elucidated, conditional PU.1 expression alone was also able to induce neutrophil differentiation in the APL cell line HT93A. 22 Our results in the APL cell line NB4 are in agreement with these earlier observations. In fact, in the NB4 cell line, PU.1 overexpression achieved by lentiviral transduction or ATRA Lentiviral PU.1 overexpression S Durual et al stimulation led to similar fivefold increases in PU.1 mRNA. The consequences of this upregulation were an increase in the expression of myelomonocytic surface antigens, morphologic changes compatible with differentiation into macrophages, changes in cell-cycles kinetics with diminished S-phase compatible with reduced cell proliferation and increased apoptosis. Taken together, these changes correspond to maturation of a highly proliferating immature myeloid blast into a mature, end-differentiated and non-proliferating cell with a macrophage-like phenotype, prone to apoptosis. Furthermore, we performed similar experiments in HL60 cells, another myeloid cell line without the t(15;17) translocation. Overexpression of PU.1 also led to changes in phenotype with an increased CD14 expression (Supplementary Figure 1) , and to increased apoptosis (data not shown). In the two erythroleukemic cell lines HEL and K562, a dramatic decrease in glycophorin expression was observed (Supplementary Figure  1) . Although we have not studied this in more detail, several reports imply that this inhibitory effect is most probably mediated via direct interaction of PU.1 with GATA-1, and a consecutive decrease in GATA-1 DNA binding. [8] [9] [10] [11] Threshold effects of PU.1 expression have been described previously and shown to determine myeloid versus lymphoid, and neutrophil versus macrophage differentiation. 31, 32 A detailed analysis of GFP-high and GFP-low transduced cells in our experiments showed that PU.1 levels were threefold higher in GFP-high compared to GFP-low transduced cells ( Figure 6 ). Whereas we could show that in normal precursors GFP-high cells preferentially differentiated into monocytes/macrophages and GFP-low cells into neutrophils, this effect could not be observed in the myeloid cell lines, nor in the primary blasts. Probably, reduced differentiation capacities in the malignant blasts secondary to chromosomal translocations or other genetic alterations account for this difference.
For the study of PU.1 overexpression in primary blasts, we used blast populations isolated from 12 patients with AML (Table 1) . In vitro culture of these cells is problematic, as proliferation rates are low, even in culture media supplemented with various growth factors or conditioned supernatants. In our experiments proliferation rates and blast turnover were equally low and probably explain the low transduction efficiency we observed in our primary blasts compared to the one obtained with cell lines (Figure 4a ). Nevertheless, transduced cells showed increases in PU.1 mRNA (Figure 4b ) and increases in myelomonocytic surface antigen expression similar to the ones obtained with cell lines. These changes were observed in all samples studied, independent of the leukemia subtype and independent of the presence of the t(15;17) (Figure 4c and d) . A clear increase in apoptosis rates was observed in most samples. These results correspond to the results obtained with myeloid cell lines and strongly suggest that myeloid differentiation is restored in primary blasts.
In addition to the experiments described above we also performed PU.1 silencing studies for which we designed a lentivector with a specific siRNA. Although we obtained an important 80 % inhibition in mRNA levels in the myeloid cell lines, we observed only minor changes in surface antigen expression, proliferation kinetics or apoptotic rates (data not shown). No effects were observed in primary blasts transduced with this vector.
We planned to study leukemic stem cells and to monitor effects of PU.1 transduction in these cells. However, phenotyping at diagnosis showed that blasts were CD34 þ in only 6/12 cases and that in the cases in which these cells could be recognized their number was too low to allow for their detailed phenotypic study after transduction (o0.01%; data not shown).
As described above, the transcription factors c-Jun and JunB are two newly discovered PU.1 target genes. Lentiviral restoration of JunB in murine PU.1 knockdown HSCs led to loss of leukemic self-renewal capacity and prevented leukemia in NOD-severe combined immunodeficiency mice transplanted with these cells. 26 It would therefore be interesting to study whether the effects on myeloid differentiation, which we have observed in AML blasts with PU.1 overexpression, could be obtained by one or both of the Jun genes.
In summary, PU.1 as the 'master regulator of myelopoiesis', constitutes an interesting target for future therapeutic interventions, as overexpression of PU.1 in myeloid blasts from different AML subtypes induced phenotypic and apoptotic changes characteristic of restored blast cell differentiation.
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